AM

Anil Mahadeo Patil

Active Director Director DIN 10871332
DIN 10871332 First appointment Dec 2024
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Anil Mahadeo Patil

Data last updated:

Anil Mahadeo Patil is a Director at Bestritz Pharma Private Limited (since 2024).

DIN 10871332
Primary Designation Director
First Appointment 20 Dec 2024
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Bestritz Pharma Private Limited U86100MH2024PTC436108
Director20 Dec 20242024Active

Directorship timeline

Open interactive timeline →
Bestritz Pharma Private Limited
Premium access

Shareholding and investment profile for Anil Mahadeo Patil

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Anil Mahadeo Patil

Anil Mahadeo Patil currently holds 1 directorship: Bestritz Pharma Private Limited (Director, since 20 Dec 2024).

Anil Mahadeo Patil was first appointed on 20 Dec 2024 as Director at Bestritz Pharma Private Limited.

The current boards of Anil Mahadeo Patil's companies include Dipankar Chudaman Bhivgade (Bestritz Pharma Private Limited), Kuldeep Jagoji Dongre (Bestritz Pharma Private Limited), Manish Maroti Gambhir (Bestritz Pharma Private Limited), Pradnya Vinod Gambhir (Bestritz Pharma Private Limited), Raibhan Shriram Dongre (Bestritz Pharma Private Limited), Ratnakar Tularam Walde (Bestritz Pharma Private Limited), among others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available